<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04627350</url>
  </required_header>
  <id_info>
    <org_study_id>R01</org_study_id>
    <nct_id>NCT04627350</nct_id>
  </id_info>
  <brief_title>Early Detection of Lung Cancer in Czech High-risk Asymptomatic Individuals</brief_title>
  <acronym>ELEGANCE</acronym>
  <official_title>Early Detection of Lung Cancer in Czech High-risk Asymptomatic Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charles University, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General University Hospital, Prague</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Charles University, Czech Republic</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to evaluate and optimize entry criteria for the proposed programme&#xD;
      for early detection of lung cancer in the Czech Republic.&#xD;
&#xD;
      An estimated 3200 high-risk (age 55-74 years, &gt;30 pack-years) asymptomatic individuals will&#xD;
      undergo baseline low-dose chest CT (LDCT) and a follow-up LDCT at 1 year. Patients with poor&#xD;
      performance status (PS) 2-4, history of malignancy in the past 10 years, chest CT in the past&#xD;
      1 year, bodyweight &gt;140kg will not be included.&#xD;
&#xD;
      The patients will fill out a questionnaire with basic data, including smoking history&#xD;
      (pack-years), history of previous malignancy, CT imaging of the thorax, and will undergo&#xD;
      spirometry.&#xD;
&#xD;
      Outcomes of the study include:&#xD;
&#xD;
        -  optimization of entry criteria, optimization of timing of a follow-up LDCT and&#xD;
           management of the patients, proposal of quality assurance indicators&#xD;
&#xD;
        -  influence of screening on the stage of lung cancer at the time of the diagnosis and&#xD;
           life-years lost&#xD;
&#xD;
        -  cost-effectiveness of the screening program&#xD;
&#xD;
        -  evaluation of the diagnostic yield for secondary findings (pulmonary fibrosis,&#xD;
           cardiovascular risk)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of cancers detected at stage I</measure>
    <time_frame>2023</time_frame>
    <description>The proportion of cancers diagnosed at a resectable stage (stage I) vs. non-resectable stage (II-IV) will be compared to the stage distribution in an unscreened population</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The cost per diagnosis at a resectable stage</measure>
    <time_frame>2023</time_frame>
    <description>The cost per diagnosis at a resectable stage will encompass the cost of low-dose CT (LDCT), follow-up LDCT, verification (PET/CT, tissue sampling, bronchoscopy).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Number of secondary examinations</measure>
    <time_frame>2023</time_frame>
    <description>The number, cost, and complications of secondary examinations generated by screening LDCT.</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of secondary findings</measure>
    <time_frame>2023</time_frame>
    <description>The number and types of secondary findings and their clinical relevance (potentially important vs. unimportant findings) will be reported.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">3200</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>LDCT</arm_group_label>
    <description>Single arm - all patients undergo low-dose CT (LDCT) examination of lungs</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Response to pulmonary finding (nodule, mass)</intervention_name>
    <description>Follow-up low-dose CT, PET-CT, tissue sampling (transparietal biopsy, bronchoscopy, resection), contrast-enhanced CT of the thorax</description>
    <arm_group_label>LDCT</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Defined by eligibility criteria&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 55-74 years&#xD;
&#xD;
          -  Smoking: &gt;= 30 pack-years, smoker or ex-smoker &lt;15 years&#xD;
&#xD;
          -  Performance status (0-1) - can climb at least one floor without any difficulty or&#xD;
             pause&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body weight above 140 kg&#xD;
&#xD;
          -  Malignant disease within the last 10 years (except non-melanoma skin cancer).&#xD;
&#xD;
          -  Chest CT less than one year ago&#xD;
&#xD;
          -  Clinical signs suspicious of lung cancer (weight loss, new cough, hemoptysis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lukas Lambert, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>General University Hospital in Prague</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lukas Lambert, M.D.</last_name>
    <phone>+420224962232</phone>
    <email>lambert.lukas@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>General University Hospital in Prague</name>
      <address>
        <city>Prague</city>
        <zip>12808</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lukas Lambert</last_name>
      <phone>+420 224962232</phone>
      <email>lambert.lukas@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>August 27, 2020</study_first_submitted>
  <study_first_submitted_qc>November 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>November 7, 2020</last_update_submitted>
  <last_update_submitted_qc>November 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 13, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>General University Hospital, Prague</investigator_affiliation>
    <investigator_full_name>Lukas Lambert</investigator_full_name>
    <investigator_title>Associated professor</investigator_title>
  </responsible_party>
  <keyword>lung cancer</keyword>
  <keyword>low dose CT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is no plan to share individual participant data.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

